EQS Group-Ad-hoc: Kuros Biosciences AG / Key word(s): Miscellaneous 
Kuros to receive USD7 million up front and potentially USD166.5 million in future revenues under a royalty purchase 
agreement with XOMA related to Kuros's license agreement with Checkmate Pharmaceuticals 
15-Jul-2021 / 07:00 CET/CEST 
Release of an ad hoc announcement pursuant to Art. 53 LR 
The issuer is solely responsible for the content of this announcement. 
=---------------------------------------------------------------------------------------------------------------------- 
Ad hoc announcement pursuant to Article 53 of the SIX listing rules 
Schlieren (Zurich), Switzerland, 15 July, 2021 - Kuros Biosciences AG ('Kuros' or the 'Company'), a leader in next 
generation bone graft technologies, announced today that it has entered into a royalty purchase agreement with XOMA 
Corporation (NASDAQ: XOMA) under which XOMA has purchased a proportion of the potential future pre-commercial milestone 
payments and all the potential royalties due under the existing license agreement between Kuros and Checkmate 
Pharmaceuticals related to one of Kuros's assets outside of the bone graft field.  Kuros will receive an initial 
payment of USD7 million from XOMA.  In addition, Kuros retains the potential to receive up to USD24 million in 
pre-commercial milestones from Checkmate, and is eligible to receive up to USD142.5 million in sales milestones from 
Xoma. 
Under the 2015 licensing agreement with Kuros, Checkmate is investigating vidutolimod (CMP-001), an advanced generation 
Toll-like receptor 9 (TLR9) agonist, delivered as a biologic virus-like particle utilizing a CpG-A oligodeoxynucleotide 
as a key component, across multiple tumor types in combination with several checkpoint inhibitor immunotherapies. 
Checkmate is conducting multiple clinical trials, including two phase 2 trials in the melanoma indication, which have 
already triggered two milestone payments of USD2 and USD4 million by Checkmate earlier this year. These milestone payments 
together with the payment from the royalty purchase agreement announced today amount to USD13 million in revenue to Kuros 
in 2021. 
Joost de Bruijn, Chief Executive Officer of Kuros, commented: 'This transaction with XOMA offers a unique opportunity 
for Kuros to secure meaningful capital, while keeping significant downstream payment potential upon successful 
development of vidutolimod by Checkmate. The proceeds will allow Kuros to further invest in our core business, 
including commercialization of our MagnetOs bone graft and the clinical development of Fibrin-PTH, which is a 
substantial commercial opportunity.' 
 
For further information, please contact: 
Kuros Biosciences AG         LifeSci Advisors 
Michael Grau                 Hans Herklots 
Chief Financial Officer      Investors 
t: +41 44 733 47 47          t: +41 79 598 7149 
e: michael.grau@kurosbio.com e: hherklots@lifesciadvisors.com

About Kuros Biosciences AG Kuros Biosciences is a leader in next generation synthetic bone graft technologies for targeted and controlled bone healing. Kuros's bone graft substitute, MagnetOs, is commercialized in the US and UK for use in posterolateral spinal fusions. Kuros's lead product in development, Fibrin PTH, a drug-biologic combination for spinal interbody fusion, has entered a phase 2 clinical trial in the U.S. Kuros is located in Schlieren (Zurich), Switzerland, Bilthoven, the Netherlands and Burlington (MA), U.S.A. The Company is listed according to the International Reporting Standard on the SIX Swiss Exchange under the symbol KURN. Visit www.kurosbio.com for additional information on Kuros, its science and product pipeline. Forward Looking Statements This media release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. You are urged to consider statements that include the words 'will' or 'expect' or the negative of those words or other similar words to be uncertain and forward-looking. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include scientific, business, economic and financial factors, Against the background of these uncertainties, readers should not rely on forward-looking statements. The Company assumes no responsibility for updating forward-looking statements or adapting them to future events or developments. ----------------------------------------------------------------------------------------------------------------------- End of ad hoc announcement ----------------------------------------------------------------------------------------------------------------------- 


Language:     English 
Company:      Kuros Biosciences AG 
              Wagistrasse 25 
              8952 Schlieren 
              Switzerland 
Phone:        +41 44 733 4747 
Fax:          +41 44 733 4740 
E-mail:       info@kurosbio.com 
Internet:     www.kurosbio.com 
ISIN:         CH0325814116 
Valor:        32581411 
Listed:       SIX Swiss Exchange 
EQS News ID:  1218984 
 
End of Announcement EQS Group News Service 
=------------

1218984 15-Jul-2021 CET/CEST


 
Image link: 
https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1218984&application_name=news

(END) Dow Jones Newswires

July 15, 2021 01:00 ET (05:00 GMT)